PMID- 24079935
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20131115
LR  - 20211021
IS  - 1757-2215 (Print)
IS  - 1757-2215 (Electronic)
IS  - 1757-2215 (Linking)
VI  - 6
IP  - 1
DP  - 2013 Sep 30
TI  - Pioglitazone counteracts the tumor necrosis factor-alpha inhibition of 
      follicle-stimulating hormone-induced follicular development and estradiol 
      production in an in vitro mouse preantral follicle culture system.
PG  - 69
LID - 10.1186/1757-2215-6-69 [doi]
AB  - BACKGROUND: Polycystic ovary syndrome (PCOS) is a common endocrine disorder in 
      women of reproductive age and is characterized by chronic anovulation. Insulin 
      resistance may be a key component of the pathogenesis of this disorder. 
      Pioglitazone is a thiazolidinedione derivative that acts by improving insulin 
      resistance via the peroxisome proliferator-activated receptor-gamma (PPAR-gamma) pathway. 
      Reportedly, pioglitazone improves the anovulation status in patients with PCOS. 
      In the present study, we examined whether pioglitazone directly affects ovarian 
      follicular development and steroidogenesis using in vitro mouse preantral 
      follicle culture system. METHODS: An isolated individual in vitro mouse preantral 
      follicle culture was used to test the effects of pioglitazone on the follicle 
      development and steroidogenesis. Tumor necrosis factor-alpha (TNF-alpha), which plays a 
      role in insulin resistance, has been reported to inhibit the follicle stimulating 
      hormone (FSH)-induced follicular development and steroidogenesis in an in vitro 
      mouse preantral follicle culture system. Therefore, we examined whether 
      pioglitazone counteracts these effects by TNF-alpha. We assessed the follicle 
      diameter and follicle survival and antral-like cavity formation rates, the 
      17beta-estradiol (E2) levels in the culture medium, and the ovulation rate using the 
      in vitro preantral follicle culture. RESULTS: Pioglitazone treatment counteracted 
      the inhibition of TNF-alpha in FSH-induced follicle development in a dose-dependent 
      manner. Pioglitazone, at a concentration of 5 muM, which was the minimum effective 
      concentration, significantly counteracted the inhibition of TNF-alpha in FSH-induced 
      follicle survival (29 versus 56%, P < 0.05), antral-like cavity formation (29 
      versus 48%, P < 0.05), E2 concentration in the culture medium 
      (mean +/- SEM = 21 +/- 1 versus mean +/- SEM = 27 +/- 1 pg/mL, P < 0.05), and human 
      chorionic gonadotropin-induced ovulation rate (9 versus 28%, P < 0.05). 
      CONCLUSIONS: Pioglitazone counteracted the inhibition by TNF-alpha on FSH-induced 
      follicle development and steroidogenesis in the in vitro mouse preantral follicle 
      culture. The results suggest that pioglitazone may directly affect the follicular 
      development and steroidogenesis.
FAU - Hara, Shuichiro
AU  - Hara S
AD  - Department of Obstetrics and Gynecology, Yamagata University Faculty of Medicine, 
      Yamagata 990-9585, Japan. totakaha@med.id.yamagata-u.ac.jp.
FAU - Takahashi, Toshifumi
AU  - Takahashi T
FAU - Amita, Mitsuyoshi
AU  - Amita M
FAU - Matsuo, Koki
AU  - Matsuo K
FAU - Igarashi, Hideki
AU  - Igarashi H
FAU - Kurachi, Hirohisa
AU  - Kurachi H
LA  - eng
PT  - Journal Article
DEP - 20130930
PL  - England
TA  - J Ovarian Res
JT  - Journal of ovarian research
JID - 101474849
PMC - PMC3849627
EDAT- 2013/10/02 06:00
MHDA- 2013/10/02 06:01
PMCR- 2013/09/30
CRDT- 2013/10/02 06:00
PHST- 2013/08/12 00:00 [received]
PHST- 2013/09/17 00:00 [accepted]
PHST- 2013/10/02 06:00 [entrez]
PHST- 2013/10/02 06:00 [pubmed]
PHST- 2013/10/02 06:01 [medline]
PHST- 2013/09/30 00:00 [pmc-release]
AID - 1757-2215-6-69 [pii]
AID - 10.1186/1757-2215-6-69 [doi]
PST - epublish
SO  - J Ovarian Res. 2013 Sep 30;6(1):69. doi: 10.1186/1757-2215-6-69.